Clinical Scorecard: Link Between the C-Reactive Protein–Triglyceride–Glucose Index and Coronary Heart Disease in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Analysis

At a Glance

Key Highlights

• 387 out of 611 patients with MASLD had coronary heart disease (CHD).
• C-reactive protein–triglyceride–glucose index (CTI) was independently associated with CHD.
• Higher CTI levels corresponded to greater coronary stenosis severity.
• CTI showed better discriminative ability for CHD than other insulin resistance indices.
• A nomogram for individualized CHD assessment was developed and validated.

Guideline-Based Recommendations

Diagnosis

• Use CTI for assessing CHD risk in patients with MASLD.

Management

• Consider further cardiovascular evaluation for patients with elevated CTI.

Monitoring & Follow-up

• Monitor CTI levels as part of cardiovascular risk stratification.

Risks

• Increased risk of CHD associated with higher CTI levels.

Patient & Prescribing Data

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

CTI may aid in identifying patients at risk for CHD.

Clinical Best Practices

• Incorporate CTI into routine cardiovascular risk assessments for MASLD patients.
• Utilize the developed nomogram for individualized CHD risk evaluation.

Related Resources & Content

• Study on CTI and cardiovascular risk